Pacific Biosciences of California (NASDAQ:PACB) Price Target Cut to $2.00 by Analysts at Scotiabank
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price objective lowered by analysts at Scotiabank from $6.00 to $2.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the biotechnology company’s stock. Scotiabank’s price target points to a potential upside of 57.48% from the […]
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price objective lowered by analysts at Scotiabank from $6.00 to $2.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the biotechnology company’s stock. Scotiabank’s price target points to a potential upside of 57.48% from the […]
